Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Cathie Wood's ARK buys CRSP, sells TDOC stock

EditorFrank DeMatteo
Published 05/22/2024, 09:18 AM
© Reuters
SHOP
-
TDOC
-
CRSP
-

Cathie Wood's ARK ETF published their daily trades for Tuesday, May 21st, 2024, revealing a series of strategic buy and sell moves in the biotech and tech sectors. At the forefront of these trades was a significant investment in CRISPR Therapeutics AG (NASDAQ:CRSP), with ARK purchasing 86,868 shares split between its ARKK and ARKG ETFs, totaling a substantial $4,818,568. This move underscores ARK's continued confidence in gene-editing technology, reflecting a broader trend of ARK's increasing stake in CRSP over recent trading sessions.

In contrast, ARK divested a large portion of its holdings in Teladoc Health Inc (NYSE:TDOC), selling 374,915 shares across ARKK and ARKG, amounting to $4,611,454. This sale represents the continuation of a shedding trend for TDOC, observed in ARK's activities over the past week.

Another notable trade included the purchase of 34,566 shares of e-commerce giant Shopify Inc (NYSE:NYSE:SHOP) through its ARKF ETF, injecting $2,036,283 into the online retail platform. This investment aligns with ARK's pattern of bolstering its position in SHOP, as seen in previous days' trades.

ARK also expanded its biotech portfolio by buying 109,691 shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) for $393,790 through ARKG, and 16,152 shares of Intellia Therapeutics Inc (NASDAQ:NTLA) for $418,175, split between ARKK and ARKG. Both actions reflect ARK's ongoing interest in the rapidly evolving biotech industry.

On the selling side, ARK reduced its exposure to Robinhood Markets Inc (NASDAQ:HOOD) by offloading 39,105 shares through ARKF, equating to $814,948. This follows a pattern of selling HOOD shares in the days prior, suggesting a strategic shift away from the brokerage platform.

Other sales included a minor reduction in the ARK 21Shares Active Bitcoin Futures Strategy ETF (BATS:ARKA), with 1,770 shares sold for a modest $4,160, and a slight trimming of Verve Therapeutics Inc (NASDAQ:VERV) holdings, selling 4,041 shares for $24,043 across ARKK and ARKG.

In summary, Cathie Wood's ARK ETFs have continued to adjust their holdings, with significant buys in CRISPR Therapeutics and Shopify, and notable sells in Teladoc Health and Robinhood Markets. These trades reflect ARK's strategic positioning within sectors it believes are poised for future growth, while also managing its exposure to assets it deems less favorable in the current market landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.